Fundamenta Therapeutics, Ltd.
- Country
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
6
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:6
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (100.0%)Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia
Phase 1
Not yet recruiting
- Conditions
- Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
- Interventions
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Fundamenta Therapeutics, Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT05576181
Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies
Phase 1
- Conditions
- T-cell Acute Lymphoblastic LymphomaT-Acute Lymphoblastic LeukemiaT-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Fundamenta Therapeutics, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05127135
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei, Anhui, China
🇨🇳Fundamenta Therapeutice Co.,Ltd, Suzhou, Jiangsu, China
Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
Phase 1
Recruiting
- Conditions
- B-cell Malignancy
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Fundamenta Therapeutics, Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05106907
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma
Phase 1
Recruiting
- Conditions
- B-cell Malignancy
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Fundamenta Therapeutics, Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05106946
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies
Phase 1
- Conditions
- B Cell Malignancy
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- Fundamenta Therapeutics, Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04601181
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei, Anhui, China
- Prev
- 1
- 2
- Next
News
No news found